MNPR
Monopar Therapeutics Inc.71.47
-3.65-4.86%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
477.60MP/E (TTM)
-Basic EPS (TTM)
-3.96Dividend Yield
0%Recent Filings
8-K
8-K
Monopar raises $91.9M via offering
Monopar Therapeutics launched an underwritten offering on September 23, 2025, selling 1,034,433 common shares at $67.67 each and 960,542 pre-funded warrants, netting ~$91.9 million after repurchasing 550,229 shares from affiliate Tactic Pharma at $63.6098 per share. The cash bolsters its clinical-stage pipeline, including ALXN1840 for Wilson disease. A new peer-reviewed letter shows ALXN1840 rapidly improves copper balance in patients. Funding strengthens development runway.
8-K
ALXN1840 shows long-term neurological gains
Monopar Therapeutics unveiled new data at the 150th American Neurological Association Annual Meeting on September 14-15, 2025, showing ALXN1840's sustained neurological improvements over six years in Wilson disease patients from pooled trials (n=255), including reversals in those switching from standard care. Safety remained strong, with under 1% drug-related neurological serious adverse events across 645 patient-years. These findings bolster ALXN1840's potential for neurological and hepatic benefits. Regulatory uncertainties loom large.
8-K
Monopar's Q2 loss widens
Monopar Therapeutics reported a Q2 2025 net loss of $2.5 million, up from $1.7 million last year, driven by higher R&D and G&A expenses amid pipeline advances. The company took full control of ALXN1840 for Wilson disease on June 6, 2025, gearing up for an NDA filing in early 2026, while MNPR-101 radiopharma trials enroll in Australia and the U.S. Cash stands at $53.3 million, funding operations through 2026. Regulatory hurdles loom large.
10-Q
Q2 FY2025 results
Monopar Therapeutics posted a Q2 net loss of $2.5M, up 43% y/y from $1.7M, driven by higher R&D at $1.7M (53% y/y rise) and G&A at $1.5M (129% y/y jump, tied to stock-based comp). YTD net loss widened to $5.1M from $3.4M y/y, with operating loss matching net at $6.5M after $1.4M interest income offset. EPS came in at -$0.35 quarterly, reconciling to 7.0M diluted shares with no anti-dilution flagged. Cash burned $6.7M in operations, leaving $53.3M in cash and investments at quarter-end, funding runway through 2026. Alexion transferred ALXN1840 IND sponsorship in June 2025, paving NDA path despite prior termination. Yet regulatory approval remains uncertain.
ALLR
Allarity Therapeutics, Inc.
1.07+0.01
ALXO
ALX Oncology Holdings Inc.
1.43+0.03
APRE
Aprea Therapeutics, Inc.
0.91-0.01
LTRN
Lantern Pharma Inc.
3.33-0.04
MRKR
Marker Therapeutics, Inc.
1.27-0.12
MRSN
Mersana Therapeutics, Inc.
29.05+0.46
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
RADX
Radiopharm Theranostics Limited
5.99-4.64
RPTX
Repare Therapeutics Inc.
2.23+0.03